Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist

Johannes Jacob Pieter Kastelein

Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $15.5M

Reported trades

Filed Stock Type Shares Price Value Since
Oct 2SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 50,24669,302 held (−42%) $25.03 $1.3M -13.8%
Aug 25SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 125,00069,302 held (−64%) $26.91 $3.4M -19.8%
Mar 9SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 104,46769,302 held (−60%) $30.30 $3.2M -28.8%
Mar 9SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 94,12469,302 held (−58%) $30.32 $2.9M -28.8%
Mar 9SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 101,40969,302 held (−59%) $30.29 $3.1M -28.8%
Feb 24SEC NAMSNewAmsterdam Pharma Co N.V. Sell 14,69284,289 held (−15%) $35.00 $514K -38.4%
Feb 24SEC NAMSNewAmsterdam Pharma Co N.V. Sell 30,78953,500 held (−37%) $35.46 $1.1M -39.2%
Jan 7SEC NAMSNewAmsterdam Pharma Co N.V. Sell Plan 6,00073,481 held (−8%) $33.25 $200K -35.1%
  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $1.3M of NAMS at $25.03 — cuts the stake by 42%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $3.4M of NAMS at $26.91 — cuts the stake by 64%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $3.2M of NAMS at $30.30 — cuts the stake by 60%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $2.9M of NAMS at $30.32 — cuts the stake by 58%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $3.1M of NAMS at $30.29 — cuts the stake by 59%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Johannes Jacob Pieter Kastelein sold $1.1M of NAMS at $35.46 — cuts the stake by 37%.